182TiP Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA1/2-mutated (gBRCAm) or homologous recombination deficient (HRD), hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ABC). The LUZERN Strategy

Autor:	A. Llombart Cussac, S. Blanch, J de la Haba, P. Palacios-Ozores, Judith Balmaña, Andreu Prat, M. Ramos, Emiliano Zamora de Alba, J. Cortés, Andrea Malfettone, J. A. Garcia Saenz, José E. Alés-Martínez, M. Sampayo-Cordero, L. Lema, Jose Perez-Garcia
Rok vydání:	2020
Předmět:	biology business.industry Advanced breast Cancer Hematology medicine.disease Oncology Hormone receptor biology.protein Cancer research Medicine Aromatase Homologous recombination business Human Epidermal Growth Factor Receptor 2
Zdroj:	Annals of Oncology. 31:S82
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.03.282
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c77bcb5907f583d3bb774968061ff1c7 https://doi.org/10.1016/j.annonc.2020.03.282 Zobrazit plný text záznamu